Search results
Checking in on Regeneron Pharmaceuticals, Inc.
Knox Daily· 13 hours agoRegeneron Pharmaceuticals, Inc.’s filing revealed that its EVP Commercial McCourt Marion unloaded Company’s shares for reported $0.24 ...
Regeneron Pharmaceuticals, Inc. [NASDAQ: REGN] Sees Decrease in Stock Value – Knox Daily
Knox Daily· 6 days agoThe buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Regeneron Pharmaceuticals, ...
Truist Financial Corp Sells 8,062 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 3 days agoTruist Financial Corp reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 15.4% in the fourth ...
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday...
Zacks via Yahoo Finance· 7 days agoStocks recently featured in the blog include: Danaher Corp. DHR,Regeneron Pharmaceuticals, Inc....
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 2 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Zacks via Yahoo Finance· 2 days agoIts earnings beat estimates in each of the trailing four quarters, delivering an average earnings...
EYLEA HD shows promise in long-term clinical trials By Investing.com
Investing.com· 2 days agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) today revealed positive long-term...
Peninsula biotech co-founded by Jennifer Doudna lands CRISPR gene-editing pact with Regeneron -...
The Business Journals· 7 days agoTrying to deliver compact CRISPR-based gene-editing packages to new places in the body, Regeneron ...
Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies
Seeking Alpha· 7 days agoRegeneron Pharmaceuticals and Mammoth Biosciences join forces to develop CRISPR-based gene editing...
Cencora beats profit estimates on strong demand for costly specialty drugs
Reuters· 16 hours ago, opens new tab beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid ...